SB3677, the Dietary Supplement Listing Act of 2026, would require manufacturers, packers, distributors, or U.S. agents responsible for dietary supplements sold in the United States to submit product listings to the Secretary of Health and Human Services, through the FDA. The required listing information is extensive and includes product identity, responsible party contact information, an electronic label copy, ingredient and serving information, directions for use, warnings, allergen statements, product form, and certain label claims. The bill also creates a product listing number for each supplement and directs FDA to establish a publicly searchable electronic database of listed products within two years of enactment.
The bill is designed to increase transparency and improve the availability of information about dietary supplements in interstate commerce. It sets different timing rules for products already on the market versus new products, requires notice when products are discontinued, and requires updates within 30 days for label changes. It also authorizes appropriations to support FDA implementation and adds a misbranding provision for supplements that should have been listed but were not, as well as a prohibited act involving supplements handled by a debarred person.
The bill’s impact on state laws is indirect, because it amends the federal Food, Drug, and Cosmetic Act rather than state statutes. Its practical effect would be to impose new federal compliance obligations on supplement manufacturers and related responsible persons, while giving FDA a new national inventory and public database of dietary supplement products. The bill also preserves FDA’s existing inspection and record-access authority and explicitly states that it does not create premarket approval authority for supplements.
Overall sentiment in the available record appears neutral to supportive, but limited, because there are no committee transcripts or recorded votes included. The bill’s stated purpose is consumer transparency and regulatory oversight, which suggests a policy rationale likely to attract support from public health and consumer protection advocates. At the same time, the absence of debate in the record means there is no documented opposition or endorsement beyond the bill text itself.
The main points of contention likely concern regulatory burden, confidentiality, and the scope of FDA authority. Industry stakeholders may object to the administrative costs of mandatory listing, ongoing updates, and public disclosure of product information, while the bill attempts to address privacy and trade-secret concerns by withholding certain information, including proprietary blend quantities and sensitive business-location data. Another possible issue is that the bill increases reporting and enforcement requirements without creating premarket approval, which may be seen as either a balanced transparency measure or an insufficient safeguard depending on the stakeholder.
The bill would amend the federal Food, Drug, and Cosmetic Act to create a new federal dietary supplement listing regime, add a misbranding trigger for noncompliance with listing obligations, and make it a prohibited act to introduce supplements prepared or handled with the assistance of a debarred person. It would require FDA to maintain a public database of listed supplements and would impose new compliance, update, and disclosure duties on supplement firms and their U.S. agents, while expressly preserving existing FDA inspection and confidentiality rules and not authorizing premarket approval.
The available record shows no committee debate or vote history, so there is no documented partisan or stakeholder sentiment in the materials provided. Based on the bill’s text, the measure is framed as a transparency and consumer-information bill, which suggests a generally favorable policy posture, especially among public health and consumer protection interests. Any opposition would likely come from dietary supplement manufacturers or distributors concerned about added compliance costs and disclosure requirements.
The likely areas of contention are the breadth of the required disclosures, the burden of maintaining and updating listings, and the treatment of confidential business information. Supplement manufacturers and distributors may object to the administrative and operational costs of filing and updating product data, while supporters may argue that a searchable FDA database is necessary for transparency and oversight. Another point of tension is the bill’s balance between public access and confidentiality, since it protects proprietary blend quantities and certain location information from disclosure while still expanding federal reporting requirements.